Stage III Cutaneous Melanoma AJCC v7 Withdrawn Phase 1 / 2 Trials for Nivolumab (DB09035)
| Indication | Status | Phase |
|---|---|---|
| DBCOND0091046 (Stage III Cutaneous Melanoma AJCC v7) | Withdrawn | 1 / 2 |
| clinicaltrials.gov Identifier | Title | Purpose | Drugs |
|---|---|---|---|
| NCT03326258 | Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery | Treatment |